commonly used antimicrobial agents. As part of his clinical research, Charles Feldman has contributed to various multicentre international collaborative studies investigating multiple aspects of CAP. Charles Feldman’s research has been published more than 300 times, as books, book chapters, articles and abstracts. He has presented at more than 300 congresses, almost half of them international. Eva Polverino Eva Polverino is an expert in respiratory infections and is Senior Investigator at the Hospital Clinic of Barcelona (IDIBAPS, University of Barcelona, Barcelona, Spain) and Associate Professor at the University of Barcelona. She graduated in Medicine at the University of Naples (Naples, Italy) and went on to specialise in pulmonology at the University of Pisa (Pisa, Italy). After a training period at the Hospital Clinic of Barcelona focusing on gas exchange, she gained a PhD in cardiopulmonary pathophysiology at the University of Pisa. In 2007 she moved to the Department of Pulmonology at the Hospital Clinic of Barcelona, working in the field of respiratory infections. Eva Polverino is an active member of several respiratory societies: the European Respiratory Society (ERS), the American Thoracic Society (ATS), the Sociedad Espanola ˜ de Neumologıa ´ y Cirugıa´ Toracica ´ (SEPAR), and the Catalan Society of Pulmonology (SOCAP). She is currently Chair of the ERS Respiratory Infections Group, Co-Chair and member of the Steering Committee of the European Registry and Clinical Research Collaborarion in Bronchiectasis (EMBARC), and Chair of the European task force on adult non-CF bronchiectasis (ERS 2014). Eva Polverino has been an oral session facilitator and speaker at many European, American, Latin-American and Italian respira- tory congresses. She has presented more than 150 oral commu- nications at scientific congresses/courses and more than 200 communications (abstracts, posters, etc.). Eva Polverino’s personal research interests focus on respiratory infections and particularly CAP, healthcare-associated CAP, cystic fibrosis and non-cystic fibrosis bronchiectasis, and humoral immunodeficiencies, with particular attention to epidemiology, risk factors, outcome, treatment and prevention of the most relevant respiratory infections. x